Cue Biopharma Inc. Announces Appointment of Patricia Nasshorn as Chief Business Officer
December 15, 2021 at 01:00 pm
Share
Cue Biopharma, Inc. announced the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15, 2021. Ms. Nasshorn brings many years of business development, leadership and marketing experience in the healthcare industry to Cue Biopharma. Most recently, Ms. Nasshorn served as a business development consultant for several pharmaceutical companies, including Cue Biopharma, where she sought and built strategic partnerships for diverse programs. Previously, Ms. Nasshorn served as the business development executive in residence at venture capital firm, Care Capital, LLC. for 10 years, where she spearheaded partnerships for dozens of life science companies. Ms. Nasshorn’s first 20 years of her career included multiple executive, business development and marketing positions at leading healthcare companies, including Merck and Company Inc., Johnson & Johnson and Bristol-Myers Squibb. Ms. Nasshorn received her MBA from Temple University.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
CUE BIOPHARMA, INC. 
